- Poster presentation
- Open Access
- Published:
Biomarker validation of cardiac magnetic resonance analysis of regional myocardial fibrosis in ischaemic heart disease
Journal of Cardiovascular Magnetic Resonance volume 18, Article number: P77 (2016)
Background
Late gadolinium enhancement (LGE) with CMR is commonly assumed to represent myocardial fibrosis; however, comparative human histological data are limited, and there is no consensus on the most accurate method for LGE quantitation. We evaluated the relationship between CMR assessment of regional fibrosis and infarct size assessment using serial biomarkers after ST segment elevation myocardial infarction (STEMI).
Methods
Ninety-five patients treated for STEMI (59 ± 10 years, 85% male) underwent CMR six months after infarction. Fibrosis was quantified by CMR-LGE using visual and automated thresholds, and compared with the rise in serum biomarkers.
Results
Quantification methods had a strong influence on the infarct size assessment with CMR-LGE. Significant correlations were observed between LGE and biomarkers across a range of signal intensity thresholds (range: 2-10 standard deviations [SD] above reference myocardium), however there was a wide range with respect to estimation of total LGE size (from 6.8 ± 7.7 to 32.1 ± 11.3 grams) and a smaller variation in the correlation with peak troponin level (R-values ranging from 0.715 to 0.834). The strongest correlation was observed at thresholds of 5 and 6 SD (R = 0.830, P < 0.001 and R = 0.834, P < 0.001).
Conclusions
There is a wide variation for the correlation between CMR-LGE quantification of infarct size and biomarker release following STEMI at a range of automated thresholds, with the strongest correlations at 5SD and 6SD thresholds.
Correlation between infarct size assessment using biomarkers and CMR-LGE.
Author information
Authors and Affiliations
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Costello, B.T., Iles, L.M., Stub, D. et al. Biomarker validation of cardiac magnetic resonance analysis of regional myocardial fibrosis in ischaemic heart disease. J Cardiovasc Magn Reson 18 (Suppl 1), P77 (2016). https://doi.org/10.1186/1532-429X-18-S1-P77
Published:
DOI: https://doi.org/10.1186/1532-429X-18-S1-P77
Keywords
- Cardiac Magnetic Resonance
- Late Gadolinium Enhancement
- Myocardial Fibrosis
- Automate Threshold
- Segment Elevation Myocardial Infarction